{"id":24309,"date":"2023-10-17T12:57:26","date_gmt":"2023-10-17T10:57:26","guid":{"rendered":"https:\/\/idibell.cat\/?p=24309"},"modified":"2023-10-17T12:58:47","modified_gmt":"2023-10-17T10:58:47","slug":"un-nou-tractament-per-prevenir-les-infeccions-que-sadquireixen-a-la-unitat-de-cures-intensives-uci-descobert-per-investigadors-de-lidibell-i-de-lhospital-universitari-de-bellvitge-entra-a-fase","status":"publish","type":"post","link":"https:\/\/idibell.cat\/2023\/10\/un-nou-tractament-per-prevenir-les-infeccions-que-sadquireixen-a-la-unitat-de-cures-intensives-uci-descobert-per-investigadors-de-lidibell-i-de-lhospital-universitari-de-bellvitge-entra-a-fase\/","title":{"rendered":"Un nou tractament per prevenir les infeccions que s’adquireixen a la Unitat de Cures Intensives (UCI) descobert per investigadors de l’IDIBELL i de l’Hospital Universitari de Bellvitge entra a Fase Cl\u00ednica"},"content":{"rendered":"

Per destruir els agents infecciosos el sistema immunitari crea anticossos \u201cespec\u00edfics\u201d contra els ant\u00edgens que els pat\u00f2gens expressen. En el moment de la infecci\u00f3 els anticossos \u201cespec\u00edfics\u201d nom\u00e9s hi s\u00f3n presents si s’ha rebut una vacunaci\u00f3 pr\u00e8via contra l’agent infecci\u00f3s.<\/p>\n

Abans que es produeixin els anticossos \u201cespec\u00edfics\u201d, als pat\u00f2gens se’ls poden unir anticossos que s\u00f3n presents a l’individu de forma natural (per exemple, els dels grups sanguinis), o que pr\u00e8viament s’han produ\u00eft contra altres agents infecciosos.<\/p>\n

El problema \u00e9s que la majoria d’aquests anticossos \u201cno espec\u00edfics\u201d no tenen capacitat destructiva davant del nou patogen. Per contra, moltes vegades aquests anticossos \u201cno espec\u00edfics\u201d poden crear un escut que evita l’actuaci\u00f3 del sistema immunitari i la superviv\u00e8ncia dels agents infecciosos, malgrat la producci\u00f3 d’anticossos \u201cespec\u00edfics\u201d contra aquests.<\/p>\n

Investigadors de l’Institut d\u2019Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL<\/a>) i de l’Hospital Universitari de Bellvitge (HUB<\/a>) han descobert que l’eliminaci\u00f3 dels anticossos \u201cno espec\u00edfics\u201d que s’uneixen als bacteris gramnegatius amb un nou f\u00e0rmac permet la resposta del sistema immunitari contra aquests bacteris, evitant que causin malalties, tal com s’ha presentat a la revista cient\u00edfica Frontiers in Immunology.<\/p>\n

Els bacteris gram negatius s\u00f3n els m\u00e0xims responsables de les infeccions que s’adquireixen dins dels hospitals, particularment a l’UCI, s\u00f3n molts resistents als antibi\u00f2tics, i no disposem de vacunes per prevenir-les.<\/p>\n

El desenvolupament de nous tractaments contra aquests bacteris \u00e9s un objectiu prioritari per a la salut p\u00fablica, com han indicat l’Organitzaci\u00f3 Mundial de la Salut (OMS), el Centre per al Control de Malalties dels Estats Units (CDC) o la Comissi\u00f3 Europea. \u201c\u00c9s la primera vegada que s’ha demostrat que es pot generar immunitat contra les infeccions eliminant anticossos existents, sense necessitat de produir-ne de nous com fan les vacunes, cosa que pot ser de gran ajuda per prevenir infeccions per a les quals no existeixen aquestes \u00faltimes, com s\u00f3n les que s’adquireixen als hospitals\u201d- apunta el Dr. Rafael Ma\u00f1ez, cap de grup de recerca de l’IDIBELL<\/a> i cap del Servei de Medicina Intensiva de l’HUB<\/a>.<\/p>\n

RemAb Therapeutics<\/a> ha dissenyat una plataforma de conjugats polim\u00e8rics mitjan\u00e7ant la tecnologia Hartful Antibody Removal Technology<\/em> (HART) a partir de la qual s’han generat f\u00e0rmacs que per primera vegada permeten l’eliminaci\u00f3 d’anticossos concrets dins del cos hum\u00e0<\/p>\n

El primer f\u00e0rmac desenvolupat per RemAb Therapeutics<\/a> \u00e9s el RA0127 que elimina els anticossos \u201cno espec\u00edfics\u201d que faciliten les infeccions causades pels bacteris gram negatius. Despr\u00e9s de confirmar l’efic\u00e0cia i la seguretat del nou f\u00e0rmac en diferents investigacions precl\u00edniques, l’Ag\u00e8ncia Espanyola de Medicaments i Productes Sanitaris (AEMPS) ha autoritzat la iniciaci\u00f3 dels assajos cl\u00ednics amb el nou f\u00e0rmac.<\/p>\n

El f\u00e0rmac \u00e9s un first-in-class-drug<\/em> que utilitza un mecanisme d’acci\u00f3 nou i \u00fanic per prevenir infeccions que s’adquireixen a l’hospital.<\/p>\n","protected":false},"excerpt":{"rendered":"

El nou tractament \u00e9s un f\u00e0rmac que permet eliminar els anticossos que s’uneixen als bacteris gram negatius i els fa resistents a la destrucci\u00f3 del sistema immunitari<\/p>\n","protected":false},"author":8,"featured_media":24310,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"set","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[1],"tags":[],"class_list":["post-24309","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sin-categorizar"],"publishpress_future_action":{"enabled":false,"date":"2025-01-29 08:58:18","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/24309","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=24309"}],"version-history":[{"count":1,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/24309\/revisions"}],"predecessor-version":[{"id":24311,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/24309\/revisions\/24311"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/24310"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=24309"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=24309"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=24309"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}